Show
Sort by
-
- Journal Article
- A1
- open access
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
-
Intramuscular hepatitis B immunoglobulins for reinfection control after liver transplantation: a cost-saving alternative
-
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study
-
Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe
-
A visual dosing aid for first-line pediatric antiretroviral treatment in resource-poor settings
-
Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy